Diabetes cell therapies take evasive action
Elie Dolgin • February 25, 2022
Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Continue reading at Nature Biotechnology.
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.